typical of CD4+ Thl cells. Serum from these mice had low or undetectable anti-B. pertussis antibody levels. In contrast, mice immunized with an acellular pertussis vaccine had high levels of B. pertussis antibodies and spleen cells secreting but not gamma interferon, a profile characteristic of CD4+ Th2 cells. Immunization with an inactivated whole-cell vaccine induced both CD4+ Thl and serum antibody responses. After exposure to a B. pertussis respiratory challenge, the convalescent mice and those immunized with the whole-cell vaccine eliminated the bacterial infection significantly faster than mice immunized with the acellular vaccine. These findings show that the selection of antigens and their form of presentation are important in determining whether the subsequent immune response is cellular, mediated by Thl cells, or humoral, mediated by Th2 cells. In the murine model, the induction of a Thl-mediated cellular immune response appears to be a key element in acquired immunity to a B. pertussis infection.
Whooping cough (pertussis), a respiratory disease caused by Bordetella pertussis, accounts for more than 300,000 deaths annually worldwide (15) . A killed whole-cell vaccine (WCV) has been available in many countries for over 40 years, and while its use seems to control pertussis epidemics, the nature of the immunity that it induces is still uncertain, and there are some doubts concerning its safety. Respiratory infection of mice, achieved by intranasal instillation (10) or aerosol challenge (43) with B. pertussis, is now a widely used model for study of the pathogenesis and immunology of this disease (29, 30, 36, 38) . This model, when it incorporates adult immunocompetent mice, is a nonlethal model with many similarities to infection observed in infants (44) . In the murine model, antibodies against the two major putative protective antigens, pertussis toxin (PT) and filamentous hemagglutinin (FHA), acquired by active immunization or passive transfer, can protect against infection (17, 20, 42) . However, a recent Swedish clinical trial of acellular pertussis vaccines failed to demonstrate a correlation between protection against clinical disease and levels of serum antibodies to PT or FHA (1) .
It is now known that B. pertussis is capable of invading eukaryotic cells (11) , and it has been found within alveolar macrophages from AIDS patients (4) . It has been suggested that cell invasion by and intracellular survival of B. pertussis may be mechanisms for persistence (13, 45) . Recent reports have demonstrated the presence of T cells specific for B. pertussis components in humans and mice following infection (9, 16, 23 Immunizations. Immunized mice each received two intraperitoneal injections comprising either half a human dose (2 IU) of the plain WCV (88/522) in 0.5 ml of PBS or 0.5 ml of the acellular vaccine (12.5 ,g each of FHA, pertactin, and PTd with 0.5 mg of aluminium sulfate) 4 weeks apart and were examined or challenged 2 weeks after the second immunization. Mice that were infected by a standard aerosol challenge with B. pertussis W28 and allowed to recover for 6 weeks, by which time they were completely free of the bacteria, formed the convalescent group. Control mice received no treatment.
Serum and lung antibody determinations. The levels of antibodies to B. pertussis components in sera and lung homogenates were estimated by use of an enzyme-linked immunosorbent assay (22) . Pertussis sonicate (5 ,ug/ml) and PT, FHA, and pertactin (2 ,g/ml each) were used to coat microtiter plates. A serum pool derived from mice 42 days after immunization with the WCV (88/522) (2 IU on days 0 and 28) was used as a reference. Serum and lung samples were centrifuged and diluted in PBS-0.05% Tween 20 prior to the assay. Bound antibodies were detected by use of alkaline phosphatase-conjugated anti-mouse immunoglobulin G (IgG), IgM, IgA, and IgE (Sigma Chemical Co., Poole, Dorset, United Kingdom). Levels of serum antibodies to each antigen preparation were estimated by assigning a nominal value of 100 U/ml to the reference serum pool. Antibody levels, expressed in units per milliliter of undiluted serum, were determined from the reference by use of a parallel-line assay. Lung homogenate IgA antibody levels were expressed as endpoint titers following dilution of original samples prepared in 1 ml of PBS.
Proliferation assay. Spleens were removed, and a singlecell suspension was prepared in RPMI 1640 medium supplemented with 2% normal mouse serum. Cells (2 x 106/ml) were incubated with heat-killed B. pertussis cells (106/ml), formaldehyde-treated sonicate (5 pLg/ml), PT (0.2 pug/ml), FHA (1 ,ug/ml), and pertactin (5 pg/ml) as previously described (23) . The proliferative responses, determined after 4 days on the basis of [3H]thymidine incorporation, were measured by scintillation counting, and the results were expressed as mean counts per minute for triplicate cultures.
Lymphokine assays. Spleen cells were cultured in the presence of B. pernussis antigens, and the supernatants were removed after the optimum times for lymphokine secretion, 24 h for IL-2 or 48 h for IL-5 and IFN--y, and stored at -20°C until assayed. IL-2 levels were assessed by measuring the growth of an IL-2-or IL-4-dependent cell line, CTLL-2, in the presence of anti-IL4 antibody IIBII, and the results were expressed as mean counts per minute for triplicate cultures. IFN-y and IL4 levels were assayed by use of an immunoradiometric assay and an immunoassay, respectively, as previously described (52); IFN-,y levels were expressed as units per milliliter relative to a reference preparation. IL-5 levels were assessed by use of an immunoassay with anti-mouse IL-5 monoclonal antibody TRFK5 for capture and biotinylated rat anti-mouse IL-5 monoclonal antibody TRFK4 (PharMingen, San Diego, Calif.) for detection, as described by Schumacher et al. (46) . Murine recombinant IL-5 (PharMingen) was used for the generation of the standard curve.
Statistical methods. Antibody, proliferation, and cytokine secretion data from the different treatment groups were compared by use of t tests.
RESULTS
Protective efficacies of immunization and previous infection. Six weeks after the initiation of primary infection or immunization, mice were infected in the respiratory tract by an aerosol challenge with B. pertussis. This resulted in a reproducible initial colonization level of approximately 3 x 10W CFU per lung (Fig. 1) . During the first 5 days of infection, nonimmunized control mice showed an increase in the number of viable bacteria of up to 100-fold. After this time, the number of bacteria in the lungs slowly declined, although more than 103 CFU per lung was still detectable 15 days after infection, but bacteria were undetectable 35 days after the challenge ( Fig. 1 and data not shown) . In contrast, in all three treatment groups, the numbers of bacteria declined soon after the challenge. Two days after the challenge, both WCV-and acellular vaccine-immunized mice showed reductions in the bacterial load that were more than 10-fold greater than that in the convalescent mice (P < 0.001). However, 5 days after the challenge, no bacteria were detectable in the lungs of convalescent mice or mice immunized with the WCV, whereas mice immunized with the acellular vaccine required much longer to clear the infection and still harbored viable bacteria 8 days after infection.
Antibody levels at the time of challenge. Six weeks after the (Fig. 4) . Cells ice were assessed against a range of B. pertussis derived from convalescent mice secreted large to moderate ns (Fig. 2a) retory IgA levels in lung homogenates (Fig. 2b) also pertussis antigens. However, these cells did produce low ed that the strongest response, in particular to FHA, levels of IL-4 (50 to 100 pgfml; data not shown) and levels of 6nerated with the acellular vaccine (P < 0.001 com-IL-5 that were significantly higher than those produced by with convalescent mice and WCV-immunized mice). cells from control, convalescent, or WCV-immunized mice mmunized with the WCV had a low level of mucosal in response to all antigens except for the B. pertussis HA IgA in the lungs, and convalescent mice showed sonicate (P < 0.01 to P < 0.001). Furthermore, T-cell lines secretory IgA responses to PT and FHA.
derived from mice immunized with the acellular vaccine ibody responses following a B. pertussis challenge. The produced high levels of IL-4 and IL-5 (2). serum and lung antibody levels were assessed 5 days postchallenge, when bacteria were no longer detectable in the lungs of the convalescent and WCV-immunized mice, and 15 days postchallenge, when the acellular vaccine-immunized mice had also cleared the infection (Fig. 3) mediated response may be induced as a result of infection or immunization with the WCV and, when induced by infection, is accompanied by only minimal antibody responses. This result is in agreement with our previous report indicating the critical role of cellular immunity in the clearance of a B. pertussis primary infection from the murine respiratory tract (24) and also demonstrates the importance of T cells in protective immunity acquired by immunization.
Until recently, pertussis was considered to be a noninvasive mucosal infection giving rise to a toxin-mediated disease (35) . Consistent with this view, most investigations of immunity to the disease have centered on humoral responses, particularly the levels of serum IgG, to selected antigens, mainly PT and putative adhesins (6, 29, 39, 42) . However, more recent findings demonstrating the invasive potential of B. pertussis (11) and the presence of antigen-specific T-cell responses following infection (9, 24, 34) have necessitated a reevaluation of potential protective mechanisms.
As previously reported by us and others (24, 34) , the time courses for the development of cellular and humoral immune responses following a respiratory infection are disparate. In naive mice, a reasonable T-cell response is detectable within 2 weeks of infection, and 3 weeks later, when the bacteria have been cleared, this response is very strong, whereas the humoral response is only just detectable. Furthermore, we have also demonstrated that adoptive transfer of immune CD4+ T cells from convalescent mice can confer protection against a subsequent challenge in the absence of a detectable antibody response (24) . Therefore, the induction of CMI is obviously crucial in the elimination of an infection in naive mice and in mice rendered immune following a respiratory infection. However, the role of antigen-specific T cells in acquired immunity generated following immunization has not been investigated.
The results of the spleen cell lymphokine secretion assays provided indirect evidence for the induction of different T-cell subpopulations by a B. pertussis infection or immunization. Recent findings have pointed to the existence of subsets of murine helper T cells, named Thl and Th2, distinguishable by the array of lymphokines they secrete (7, 26) . The secretion of high levels of IL-2 and INF--y and low levels of IL-4 and IL-5 by spleen cells from convalescent mice was typical of a Thl response, whereas acellular vaccine-immunized mice produced a lymphokine secretion profile more typical of a Th2 response, with high IL-5 and low IL-2 and IFN--y levels (27) . Although spleen cells from immunized or infected mice all produced low levels of IL-4, B. petussis-specific T-cell lines derived from mice immunized with the acellular vaccine produced high levels of IL-4 and IL-5 (2) . This observation is consistent with the demonstration that in vitro restimulation is often required to detect IL-4 production (51) and confirms the fact that the acellular vaccine induces predominantly Th2 cell types. Thl cells are predominantly effective in mediating inflammatory, cytotoxic, and delayed-type hypersensitivity responses, and Th2 cells are more efficient in providing help for antibody pro- duction (3, 7, 26) . These facts are consistent with our findings that infection induced strong T-cell proliferation and high levels of IL-2 and IFN--y production but little antibody production (cellular immunity), whereas immunization with the acellular vaccine led to a strong antibody response and the production of high levels of Th2-derived cytokines but limited T-cell proliferation (humoral immunity).
Although Th cell subpopulations with distinct cytokine secretion patterns have been more difficult to identify in humans, recent reports have demonstrated the presence of Thl and Th2 cell types following exposure to infectious agents (8, 40) . In a study of T cells from an individual who had suffered from a pertussis infection, Peppoloni et al. (33) reported that T-cell clones specific for PT and other pertussis (18, 32) . It has been shown that IFN--y produced by Thl cells inhibits the proliferation of Th2 cells (14) , and it has also been shown that IL-10 produced by Th2 cells can inhibit cytokine synthesis, especially IFN-y production, by Thl cells (12, 25) . It is therefore surprising that mice immunized with the WCV should have a lymphokine secretion profile indicative of a Thl response and yet produce a relatively high serum antibody response. The antibodies produced by B cells induced with this immunogen may not have required high levels of Th2-derived lymphokines but may have been stimulated by IL-2 or IFN--y.
There are several possible reasons for the poor efficacy of the acellular vaccine used in this study. Antigen 
